Speakers & Panels – 2019 Questrom Health & Life Sciences Conference

Friday, November 1, 2019 at the Boston University Questrom School of Business

Opening Keynote Speaker

Alan Lotvin, M.D., is executive vice president and chief transformation officer for CVS Health. In this role, Lotvin has oversight of the portfolio of business transformation initiatives across the enterprise with a focus on identifying opportunities for growth and innovation to create new health care experiences that are easier to use, less expensive and place consumers at the center of their care.

Lotvin has extensive experience in the pharmaceutical benefit management and specialty pharmacy industries. Prior to his current role, he served as executive vice president of CVS Specialty, the specialty pharmacy of CVS Health. Before joining the company, Lotvin was president and chief executive officer of ICORE Healthcare, a Magellan Health Services company. Previously, Lotvin held multiple roles at Medco Health Solutions, including president of Medco Specialty Pharmacy Services and senior vice president of Manufacturer Contracting.

Lotvin began his career as a practicing cardiologist in New Jersey. He holds a master’s degree in Medical Informatics from Columbia University and a medical degree from the State University of New York Health Sciences Center in Brooklyn. Lotvin also holds US Patent #6269819 Method and Apparatus for Circulatory Valve Repair.

The Rising Costs of Pharmaceuticals and Value Based Care

The growing cost of prescription medications continues to be a source of concern for lawmakers, providers and patients.. Trends including an influx of specialty biologics as well as stricter regulatory oversight can mean an increase in cost.  Value based care is gaining traction In an effort to incentivize quality of care over volume. As more health care providers lean towards providing value based care, how can pharmaceutical companies utilize this growing trend to offset growing costs?

Rena M. Conti is the Associate Research Director of Biopharma & Public Policy for the Boston University Institute for Health System Innovation & Policy. She is also an Associate Professor at the Boston University Questrom School of Business. From 2006 through June 2018, Professor Conti was an Associate Professor of Health Economics and Policy at the University of Chicago Medical School and the Harris School of Public Policy. Dr. Conti is a health economist. Her research focuses on the organization, financing and regulation of medical care. She has written extensively on the pricing, demand and supply of prescription drugs. She earned her PhD in Health Policy from Harvard University.

Dee Mahoney serves as the Senior Vice President and Chief Commercial Officer at Boston Biomedical, Inc. In this role, she leads the commercialization of oncology assets originating from Sumitomo Dainippon Pharma – Boston Biomedical’s parent company, Tolero Pharmaceuticals – also a wholly- owned subsidiary of Sumitomo Dainippon Pharma, and Boston Biomedical.   In addition to commercialization, Ms. Mahoney plays a leadership role in new product planning and external innovation for oncology across all companies.

Ms. Mahoney’s 30 years of experience in the biopharmaceutical industry have focused in roles ranging from field sales to executive leadership. Prior to joining Boston Biomedical, she was the Co-Founder and President of DMH BioPharm Advisors, a management-consulting firm. In this role, Ms. Mahoney partnered with biopharmaceutical companies to maximize the effectiveness of commercial strategies and reduce the risk of regulatory noncompliance.

Previously, Ms. Mahoney spent 20 years at Pfizer Inc., culminating in the role of Senior Vice President and General Manager of Pfizer’s U.S. Specialty Products Business Unit, where she was responsible for commercial operation of a $2.5 billion portfolio of oncology, anti-infective, HIV, ophthalmology and endocrine care products.

Ms. Mahoney received her Bachelor of Science degree in microbiology and organic chemistry from Stephen F. Austin State University.

Dan Lyons, MBA is the Senior Director of Value & Access for the Oncology & Transplant portfolio at Sanofi Genzyme. In his role he leads a dynamic team responsible for the pricing, reimbursement and access strategy for 6 promoted products as well as the launch planning for near term pipeline molecules. Dan has a broad commercial background with roles in sales, payer marketing, project management and operations. Dan joined Sanofi Genzyme in 2016 from Eli Lilly & Company where he focused on gaining access for patients outside of the US, specifically the EU 5 and Japan.

Sara is a Director of US Payer Marketing at EMD Serono Market Access & Customer Solution (MA&CS). She joined EMD Serono in 2016 as part of the Global MAVENCLAD Launch Team and then joined the MA&CS to continue the payer launch in the US. Her major contribution and responsibilities include development of Global & US launch pricing and contracting strategy, delivery of payer value communication tools, as well as training of countries and US corporate account teams to ensure effective access negotiation for MAVENCLAD.

Prior to joining EMD Serono, she worked as a Senior Manager in Biogen, where she secured better access for an in-line MS product, developed access strategies for emerging markets, and shaped pipeline programs for an array of neurology assets. Other experiences include: business consultant at Simon-Kucher & Partners, and scientist in cancer biology. She received her Ph.D. in pharmacology from Vanderbilt University and M.B.A degree from MIT Sloan School of Management.

Sara loves to work at the intersection of science and business and aspires to translate science to life changing innovations for patients.

Health Care Policies and Systems: Reforming the system as we know it

On the cusp of election season, Americans find themselves thinking about the fate of their healthcare. With the complexities of the two-party system, how are reforms going to take place? This panel will examine potential ramifications of how industry leaders and government representatives are looking to the future to meet the current needs of patients.

Jonathan Woodson, MD, leads Boston University’s University-wide Institute for Health System Innovation and Policy. He is a Larz Anderson Professor in Management and Professor of the Practice at the Questrom School of Business, and holds joint appointments as Professor of Surgery at the School of Medicine and Professor of Health Law, Policy, and Management at the School of Public Health.

Dr. Woodson served from 2010 to 2016 as Assistant Secretary of Defense for Health Affairs in the United States Department of Defense (DoD). He was the principal advisor to the Secretary of Defense for all health and force health protection related issues, and ensured the effective execution of the DoD medical mission. He exercised authority, direction, and control over the Defense Health Agency, Uniformed Services University of the Health Sciences, Armed Forces Radiobiology Research Institute, Defense Center of Excellence for Psychological Health and Traumatic Brain Injury, and the Tricare Health Plan—responsible for servicing 9.5 million beneficiaries. His organization provided and maintained medical readiness for the medical services including during military operations, those held in control of the military services, and those entitled to Tricare.

Anna Gosline is the Senior Director of Strategic Initiatives in the Executive Office of Blue Cross Blue Shield of Massachusetts and the Executive Director of the Massachusetts Coalition for Serious Illness Care. At Blue Cross, she manages a diverse portfolio of policy, community and communications projects that touch on topics ranging from payment reform and health care costs to the opioid epidemic. She also leads the development of corporate-wide initiatives focused on serious illness and palliative care – from payment and benefits, to provider partnerships and measurement, to community and policy work. As the Executive Director of the Massachusetts Coalition for Serious Illness Care, which is administratively housed and primary funded by Blue Cross, she leads a thriving group of more than 100 organizations across the Commonwealth who are working towards a shared vision of ensuring that health care honor individuals’ goals, values and preferences at all stages of life and health, but especially in the face of serious illness.

Previously, Anna was the Director of Policy and Research at the Blue Cross Blue Shield of Massachusetts Foundation where she oversaw the Foundation’s $1 million+ policy and research program. Before joining the Foundation, she managed a large-scale health system study for the state of Vermont. In a previous life, Anna was a health care journalist in the UK and Canada. Anna holds a master’s degree in health policy and management from the Harvard School of Public Health, a graduate certificate in science writing from the University of California, Santa Cruz and a bachelor’s degree from the University of Toronto.

Alan Sager is a professor of health law, policy, and management at the Boston University School of Public Health, where he has taught since 1983. His courses have won 14 awards. He has designed a “time banking” method of mobilizing voluntary aid for disabled citizens by creating a structured parallel economy of good deeds. His analyses of U.S. urban hospital closings over 75 years have shown that closings have harmed access while boosting costs. His BA in economics is from Brandeis and his PhD in city planning is from MIT.

Zach is the Vice President of Public Affairs at MassBio where he focuses on public policy, communications, marketing, and diversity & inclusion to support the organization and its membership.

Prior to joining MassBio, Zach was the Vice President of Public Affairs at Rasky Partners where he specialized in message development, integrated digital advocacy campaigns, public policy, and coalition building. Zach was formerly a field organizer for the Florida Democratic Party during the 2004 Kerry/Edwards Presidential Campaign, and served as the assistant to the Deputy CEO for external affairs of the 2004 Democratic National Convention in Boston.

Zach earned a bachelor’s degree in Sociology from Boston College. He lives in Westwood with his wife Jessica, their son Reed, and daughter Eleanor.

Accessible Healthcare Data: Can it be a reality?

Tension is growing between consumer demands for information and a healthcare system that is unable to provide it equitably. To design a system that functions, we must first understand barriers impeding appropriate and timely access. This panel will focus on the challenges of sharing electronic records, costs and security concerns of big data and friction between flexible access to data and flexible access to physicians.

Joseph D. Restuccia, DrPH, MPH is Professor and Chair of the Operations and Technology Management Department and Dean’s Research Scholar in the Boston University Questrom School of Business. Dr. Restuccia also holds the positions of Research Scientist at the Veterans Health Administration’s Center for Organization, Leadership and Management Research; Visiting Professor at Bocconi University in Milan, Italy; and Visiting Professor at Catholic University in Rome, Italy. His teaching and research spans over 35 years and has focused on issues related to health care quality measurement and improvement, cost containment, information technology, system transformation, and evaluation of interventions intended to improve effectiveness of health care delivery. As well as at Questrom, he has taught at BU’s Schools or Medicine and Public Health, Bocconi University, Catholic University, University of Michigan, and University of California, Berkeley. Among his activities are developing the Appropriateness Evaluation Protocol, a quality improvement instrument used internationally; co-authoring the widely-used health care Organizational Transformation Model; and publishing extensively in the health services research literature. His research has been funded with over $8,000,000 of extramural support as Principal or Co-Principal Investigator by organizations including AHRQ, VA HSR&D, HRSA, the Commonwealth Foundation, and the Robert Wood Johnson Foundation. He is currently principal investigator on a grant on Transformative Innovation for Primary Care Systems at Boston Medical Center. Dr. Restuccia has also consulted with numerous organizations in both the U.S. and in Europe on improving health care quality and productivity. He received his bachelor’s degree from Tufts University and his master’s and doctorate degrees from the University of California at Berkeley.

Amanda Centi is the Research Program Manager for Partners Healthcare Connected Health Innovation. She currently oversees a research team that is focused on testing and validating technology-based solutions in health delivery for preventive and supportive care. To keep up with the fast-paced world of digital health, Amanda’s team conducts outcomes research in new and faster ways in addition to the traditional randomized controlled trials. Amanda received her BS and MS in Exercise Physiology from Ithaca College and began her research career with the Department of Defense where she investigated modalities to increase soldier performance and decrease injury. She then returned to school and received her PhD in Biochemical and Molecular Nutrition with a focus on Pathophysiology from Tufts University before joining Connected Health Innovation. At Connected Health Innovation, Amanda enjoys working with businesses ranging from startups to Fortune 100 companies to evaluate and validate the digital health products for not only clinical and economic outcomes, but also usability and acceptability.

Laurance Stuntz is the Director of the Massachusetts eHealth Institute at MassTech, or MeHI. He is an experienced and passionate leader working to help Massachusetts leverage digital health innovation for better economic and care delivery outcomes. MeHI helps all the Commonwealth’s providers harness the benefits of electronic health records and the statewide health information exchange. As part of this effort, they work with stakeholders to ensure that patients have access to their data and become active and engaged participants in managing their health. Prior to joining MeHI in 2012, he was a Partner at Computer Sciences Corporation (CSC) with responsibility for CSC’s Collaborative Communities solution area and the Senior Vice President responsible for product development for NaviNet. Laurance is an advocate for stronger patient engagement in healthcare information and decision making, and serves as a member of the Massachusetts Health Information Technology Council, the Governor’s Digital Health Council, and the Board of Advisors for PULSE@MassChallenge. He is a Dartmouth College graduate, a Wellesley resident, and an enthusiast of outdoor sports, craft beer, and his family.

Manu serves as the Chief Information Officer for Beth Israel Deaconess Medical Center, a Harvard Medical School affiliated Academic Medical Center. In his current role, he is responsible for all IT matters pertaining to the Academic Medical Center. He directs BIDMC’s “Center for IT Exploration” which works to adopt innovative analytics, mobile, cloud and AI/ML solutions for operational efficiencies and to enhance the experience of BIDMC’s providers, patients and staff. Before joining BIDMC in 2014, Manu served as the Secretariat CIO for Massachusetts Executive Office of Health and Human Services where he led the state’s largest IT public portfolio. As Massachusetts’ state HIT Coordinator, Manu led the development of the nation’s first medicaid funded statewide Health Information Exchange (HIE) known as “MassHIWay” which has now delivered over 200 Million healthcare transactions since its inception. Manu was recognized by Computer World as one of the top “100 Premier IT Leaders” in the world and by New England HIMSS as “The CIO of the Year” for 2014. Manu has an engineering degree from Indian Institute of Technology, an MBA from Boston University and an MPA from Harvard Kennedy School.

Medicare and Medicaid: Innovation in the face of limited resources

Medicare and Medicaid is the largest sponsor insurer in the United States, but how will this insurer continue to provide services in the future? With the expansion of the ACA, state leaders have the opportunity to transform the healthcare landscape and create a system where fees can be at an all-time low. This panel will focus on payment structures, outcome metrics, and piloting new programs that are focused on redesigning care delivery.

Tal Gross is an associate professor in the Department of Markets, Public Policy & Law and a Dean’s Research Scholar at Boston University Questrom School of Business. In addition, he is also a Faculty Research Fellow at the National Bureau of Economic Research. Tal’s research focuses on health insurance and household finance. He received his bachelor’s degree from The University of Chicago and his Ph.D. from the Massachusetts Institute of Technology. He previously taught at the University of Miami School of Business Administration and the Columbia University Mailman School of Public Health.

David has over 30 years of experience, including management, technical and operations, strategic planning, marketing and business development. Current activities focus on advising and assisting US and off-shore medical technology organizations, ranging from start-ups to Fortune 500 companies, in areas ranging from opportunity analysis, marketing strategy and market development, reimbursement strategies, business development and financing. Prior to co-founding BMTA, David held senior management positions in a number of medical device companies and has founded, financed and developed a number of healthcare companies. M.Sc., Bio-Medical Engineering and Master, Business Administration, Rensselaer Polytechnic Institute, NY

Elena Nicolella is the Executive Director of the New England States Consortium Systems Organization, a private, non-profit committed to supporting State Government Health and Human Service agencies.  Elena previously worked for the State of Rhode Island’s Executive Office of Health and Human Services as the Director of Policy and Innovation and prior to that, as Medicaid Director.  Elena also worked for the Centers for Medicare and Medicaid Services in the Boston Regional Office.  She received her Master’s in Public Health from Boston University.

Marc has oversight of Tufts Health Plan’s three product lines – Commercial Products, Senior Products and Public Plans – and business diversity.  He works closely with the division presidents to identify opportunities within and across the business lines to maximize business results and continue Tufts Health Plan’s delivery of nationally recognized insurance offerings.

Marc joined Tufts Health Plan in 2004, and has served as president of the Commercial Products division, which has been consistently ranked among the top quality commercial plans in the country by the National Committee for Quality Assurance (NCQA). Prior that he served as senior vice president of health care services, vice president of provider contracting and vice president of strategy and product development. Prior to joining Tufts Health Plan, Marc worked for Deloitte Consulting, where he focused on the health insurance market.

Marc serves on the Greater Boston Chamber of Commerce board of directors. He is the executive sponsor of Tufts Health Plan’s Veterans and Military business resource group, that strives to build a diverse community for all current and former military service members and military allies while establishing an inclusive environment to help employees build a career, share experiences and become thought leaders. He earned an M.B.A from Harvard Business School and a B.A. from Duke University.

The Role of AI and Digital Health in Creating New, Cost-Effective Solutions

Artificial intelligence (AI) has transformed the way we do business and our everyday lives. Virtual assistants, computer-aided diagnosis and clinical decision support are just a few examples of how artificial intelligence in healthcare has transformed the sector. With these new advancements there are a multitude of opportunities for growth, but will these services be available to address the needs of the cost-conscious or is it a service for an elite few? This panel will focus on opportunities and challenges that come with AI technology and the room for growth to provide services in a cost-effective way. With new technology introduced every day, how will new players provide effective solutions to cutting cost and providing top of the line care?

Jayakanth “JK” Srinivasan is a Research Associate Professor at Boston University’s Questrom School of Business, and a Fellow at the Institute for Health Systems Innovation and Policy. Prior to joining BU, he led a research team at MIT working with the Army over a five-year period to iteratively transform behavioral health services for Soldiers and their families. He has also served as a faculty member at the School of Innovation, Design and Engineering at MDH in Sweden.
Prof. Srinivasan is an excellent source of information for systems analysis and health system transformation, with a focus on system redesign, modeling and analytics, performance management, and change implementation. His current research projects focus on: understanding how leader sensemaking and sensegiving can improve individual and organizational health outcomes; and enabling precision medicine in behavioral healthcare settings.
He is the recipient of the Commander’s Award for Public Service, the Army Outstanding Civilian Service Award, and is a senior member of the ACM.

Dr. Debbie Lin is Executive Director at Boehringer Ingelheim Venture Fund in the US and leads the Fund’s North American efforts in Digital Healthcare.   She joined Boehringer Ingelheim Pharmaceuticals in 2008. Within Boehringer Ingelheim Pharma, she worked across various regions and divisions. She has worked in Medical Affairs in the area of women’s health and later in Health Economics and Outcomes supporting all commercial product sales with large payers and providers accounts on the West Coast.  She also led the US organization’s social entrepreneurship program in Boehringer Ingelheim’s Making More Health collaboration with Ashoka. In 2013, she transitioned to Corporate Headquarters in Germany in Corporate Strategy and Development as Director of Corporate Development. There she was responsible for BI’s global development strategy, leading BI’s global venture into stroke rehabilitation.  She led multi-country teams to set up the company’s first stroke rehabilitation centers in Shanghai, China and in Lisbon, Portugal. Prior to Boehringer Ingelheim, she worked as a Public Policy Consultant for Pacific Health Policy Group supporting Medicaid Policy implementation in various states such as Vermont and West Virginia during the Clinton Administration. Her doctorate is in Pharmacogenomics and Bioinformatics from UCSF, she also has a Masters in Engineering from Stanford University and a Masters in Public Policy from UCLA.   Debbie is a native Californian, she loves sunshine, being around nature and the ocean, yoga and dogs.

Sachin is an experienced healthcare executive and digital health entrepreneur. He is currently a Senior Business Lead on the Healthcare team at Google. There he leads a team that builds joint business plans and digital marketing strategies with C-level executives at global pharmaceutical companies.

Prior to joining Google and Facebook, Sachin was the Co-founder and CEO of Docphin.  Sachin led a team of engineers, designers and sales professionals to build a digital media platform with over 60,000 physician members. Docphin was selected by Apple as one of the “Best New Apps for Medical Professionals” in 2014. In January 2016, Docphin was acquired by HealthTap.

Before starting Docphin, Sachin was a Senior Consultant at IMS Consulting Group, managing global pricing and market access engagements for Pharmaceutical clients primarily in oncology.

Sachin is passionate about building, developing and empowering high performing teams that drive strong business impact. He received his MBA from Columbia Business School and BA in Economics from the University of Michigan. Prior to business school, Sachin was an award winning sales professional for GlaxoSmithKline and Novartis Pharmaceuticals.

Dr. Sunita Patolia leads the Human-Centered Design team focused on understanding the needs and gaps in our current healthcare services and delivery and create solutions that are tailor-made to solve those problems in a human-centric way. Sunita’s role over the last few years at Partners has also involved managing the innovation programs aimed at building a community of cross-functional healthcare professionals to re-imagine the healthcare experience. In her role, Sunita actively designs workshops and experiences that take her team, as well as clinical and non-clinical groups at Partners HealthCare, on an exploration of their own creative confidence while identifying and solving problems together. She has led projects focused on establishing strategic partnerships with healthcare industry partners for designing empathetic patient experience, new product development and user centered experience for care team. Sunita’s work combines Design Thinking methodology for problem solving with the Theory U innovation model for mobilizing change within organizations. Dr. Patolia is a Pharmacist who earned her PhD in Cell and Molecular Biology from University of Wisconsin, Madison. Her expertise in innovation models and Action Learning was developed under Dr. Karen Tilstra’s tutelage at Florida Hospital Innovation Lab.

Women’s Health: At the cusp of a new era

“Femtech” is one of the fastest growing sectors to invest in and it is anticipated to hold major weight in the healthcare industry in the years to come. The momentum has gained significant traction and these companies are ideally positioned to engage patients as new opportunities emerge. This panel will focus on the opportunities and challenges facing the future of women’s health and the topics of fertility and maternal benefits in an ever-changing landscape.

Professor Keinan’s research interests include Branding, Symbolic Consumption, Consumer Wellness and Well-Being, Luxury Marketing, Consumer self-Control, Regret, Authenticity, and the Consumption of Experiences. She received her Ph.D. in Marketing, with distinction, from Columbia Business School. Professor Keinan is the winner of the 2011 Ferber Award for her research on collectable experiences, and the 2018 AMA Erin Anderson Award for Emerging Female Marketing Scholar and Mentor. Professor Keinan was twice ranked by the American Marketing Association as one of the Top 50 most productive Scholars in the premier marketing journals in the past 5 years. Her research was selected for the New York Times Magazine’s Year in Ideas issue, and recognized as the Journal of Consumer Research best paper award finalist in 2009, 2014, and 2017.
Her research on consumer behavior has been published in the leading marketing, psychology, and managerial journals, and featured in hundreds of media outlets, including NPR, CNN, FOX, CBS, NBC, ABC, The Wall Street Journal, The New Yorker, The Economist, Scientific American, BusinessWeek, Financial Times, Forbes, TIME, Boston Globe, Washington Post, The Atlantic, Slate Magazine, Wired Magazine, Fast Company, Associated Press, and United Press International. She was named a Marketing Science Institute Young Scholar, and serves on the Editorial Review Board of JCR. Her research was selected in 2014 for the JCR Research Curation on “Products as Signals,” in 2015 for the Research Curation on “Meaningful Choice,” and in 2017 for the Research Curation on “Behavioral Pricing.” Prior to joining BU Professor Keinan was on the faculty of Harvard Business School for over a decade, where she received the Jakurski Family Associate Professor Chair, and the Harvard Business School Wyss Award for Doctoral Mentoring. Her HBS case studies on branding and luxury marketing have been featured in the HBS Premier Case Collection and Poets & Quants.

Shanna Deng joined the Hologic team in 2016 and is Vice President of Global Portfolio Marketing for the GYN Surgical Solutions Division with more than 12 years of commercial experience in medical device and consumer healthcare industries. She focuses on the development of new products and the expansion of new markets to drive women’s health solutions globally.
Prior to joining Hologic, Shanna ran her own consulting business for 5 years with clients such as Johnson & Johnson, Seventh Generation and AgNovos Healthcare, owning brand initiatives and launch opportunities including concept development, go-to-market strategies, and ongoing business analysis. She also held roles of increasing responsibility in Marketing at Genzyme where she managed both HCP and DTP campaigns for Seprafilm and Thyrogen, developing and executing strategies for new segments to drive incremental growth. Previously, Shanna worked for Johnson & Johnson and held brand management roles in Marketing – most notably helping to launch Listerine Total Care and multiple Sudafed PE products.
Shanna has a bachelor’s degree in Anthropology and Spanish from Cornell University and an MBA from Darden Business School.

Laila is an investor, serial entrepreneur, and Fortune 100 trained executive who enjoys working with fast growing technology companies. Over the past 12 years she has founded and lead a range of start-ups from communications technology spin-outs out of Caltech and MIT to innovative mobile and SaaS companies in retail and sustainability. Laila has strong operational and technology innovation training from her tenure at Intel Capital, Intel’s venture capital arm.

Laila is currently at Techstars as a contingent Managing Director, creating a new Boston-based accelerator. She was also an investor and group manager during Intel Capital’s formative years, investing in early enabling technologies such as RIM (the first mobile email provider) and in Red Hat and VA Linux (early leaders in the Linux/Open Source market). While at Intel, she was also part of the executive team that launched Itanium® microprocessor family; her formation of the Intel® 64 Fund provided the basis for a Harvard Business School’s case study. Since leaving Intel in 2006, Partridge has led four technology start-ups as CEO, most recently selling WegoWise to NASDAQ-traded AppFolio.

Meghan Vento has spent her 14-year career in Medical devices, first with Johnson and Johnson at DePuy Synthes Mitek Sports Medicine and most recently at Boston Scientific in both the Women’s Health and Benign Prostate Health Franchises. She has worked on both the sales and marketing sides of the business, which has given her an opportunity serve patients and physicians as well as support innovative product development. Meghan attended Villanova University and currently resides in Providence, Rhode Island with her boyfriend and their dog.